Product image of Minidiab (Glipizide) supplied by GNH India

Minidiab

Active Ingredient:
Glipizide
Origin:
EU

Minidiab (Glipizide)

Glipizide, the active ingredient in Minidiab, is a sulfonylurea presented as an oral tablet for oral use. It lowers blood glucose by stimulating insulin release from pancreatic beta cells and is indicated for the management of type 2 diabetes mellitus in adult patients. It is prescribed when diet and exercise alone are insufficient to achieve glycemic targets.

GNH India supplies Minidiab as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Manufacturer / TM Owner

Pfizer Spol. S R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glipizide is an oral sulfonylurea used to improve glycemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose by enhancing insulin secretion from pancreatic beta cells.
  • Inadequate glycemic control on metformin: adds an additional glucose‑lowering effect when combined with metformin therapy in adults.
  • Adults with diet‑controlled hyperglycemia: assists in achieving target HbA1c when lifestyle measures alone are insufficient.
  • Elderly patients with type 2 diabetes: provides effective glucose reduction, though dose may need adjustment and hypoglycemia risk requires monitoring.

How It Works

  • Glipizide binds to the sulfonylurea receptor component of the ATP‑sensitive potassium channel on pancreatic beta cells, causing channel closure. This depolarizes the cell membrane, opens voltage‑dependent calcium channels, and triggers calcium influx, which promotes insulin granule exocytosis and increases insulin secretion in response to elevated blood glucose levels.

Side Effects

Glipizide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hypoglycemia: feeling of low blood sugar, dizziness, sweating, or tremor.
  • Weight gain: modest increase in body weight during therapy.
  • Nausea: mild stomach upset or queasiness.
  • Headache: transient head pain.

Serious or Rare Side Effects

  • Severe hypoglycemia: prolonged low blood sugar requiring medical assistance.
  • Allergic reactions: rash, itching, swelling, or rare anaphylaxis.
  • Blood dyscrasias: leukopenia, thrombocytopenia, or agranulocytosis.

Precautions & Warnings

When prescribing glipizide, clinicians should consider several safety measures to minimize risk.

  • Dose adjustment in renal impairment: reduce dose or avoid in severe renal failure.
  • Monitor blood glucose regularly: to detect hypoglycemia early.
  • Use caution in elderly patients: increased sensitivity to hypoglycemia.
  • Avoid concomitant use with other sulfonylureas: risk of additive hypoglycemia.
  • Store at room temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Glipizide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Concurrent use with other sulfonylureas: additive hypoglycemia risk.
  • Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glipizide plasma levels.
  • Insulin therapy: may cause severe hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask symptoms of hypoglycemia.
  • Thiazide diuretics: can diminish glucose‑lowering effect.
  • Alcohol: may potentiate hypoglycemia, especially with fasting.

Frequently Asked Questions

Minidiab contains glipizide, a sulfonylurea oral antidiabetic that is prescribed to lower elevated blood glucose in adults with type 2 diabetes mellitus, particularly when diet, exercise, or other oral agents have not achieved target glycemic control.

Glipizide binds to the sulfonylurea receptor on pancreatic beta‑cell potassium channels, closing them and causing cell depolarisation. This opens calcium channels, leading to calcium influx that triggers insulin release, thereby reducing blood glucose levels in response to meals.

The appropriate dose of Minidiab is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of glipizide in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Minidiab product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with metformin, another first‑line oral agent, glipizide provides a rapid increase in insulin secretion and can be useful when metformin alone is insufficient. Unlike newer agents such as DPP‑4 inhibitors, glipizide carries a higher risk of hypoglycemia but is generally less expensive.

Minidiab should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Minidiab is taken orally, usually once daily with breakfast or the first main meal. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed by a healthcare professional.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as rash, swelling or anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and seek immediate medical attention if severe symptoms occur.

Minidiab is contraindicated in individuals with known hypersensitivity to glipizide or other sulfonylureas, patients with severe renal or hepatic impairment, and those with type 1 diabetes or diabetic ketoacidosis. It should also be avoided in pregnant women unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glipizide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT